Rutgers CRO has clinical research at every RBHS school on both campuses, involving hundreds of researchers. Our faculty are dedicated to moving forward discovery in drugs, biologics, devices, preventive and therapeutic strategies, behavioral research and other interventions to improve human life. We support approximately 150 industry-sponsored clinical trials on any given day of the year.
Our medical expertise spans all therapeutic areas. Significant achievement and recognition reside in Cancer, Infectious Disease, Cardiology, Oral Health, Aging and Dementia, Pediatrics, Women’s Heath, Neurology and Inflammation. Faculty also strive to innovate and improve treatment and prevention in such areas as pain management, mental illness, autism and childhood development, and surgery.
As academic specialists, our faculty have long-standing and trusted relationships with patients seeking optimum care. As investigators, their research acumen is supported by dedicated clinical staff and efficient administrative support. Rutgers conducts industry supported single and multi-site clinical trials representing all trial designs and recruitment requirements.
Please click the tabs, below, for examples of our on-going research:
Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy
The “LAPTOP-HF” trial (Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy evaluated the usefulness of a small implantable pressure sensor that measures left atrial pressure and wirelessly transmits that information to a patient activated hand held device. Key member of the national steering committee responsible for designing the randomized, controlled, prospective 700 patient over 75 centers in the country.
Alzheimer’s disease and dementia
Numerous clinical trials on Alzheimer’s disease (AD) and dementia, including, for example a study related to the treatment of cognitive function and global function in men with mild to moderate AD. This double-blind, placebo-controlled study assessed the safety and efficacy of a 48-week regimen of the drug leuprolide acetate. The total number of patients enrolled is approximately 90, with 30 subjects randomized to each of three treatment groups.
Carotid Revascularization Endarterectomy versus Stenting Trial
The Carotid Revascularization Endarterectomy versusStenting Trial (CREST) showed similar outcomes for carotid artery stenting and carotidendarterectomy for the treatment of carotid stenosis. The CREST trial comparing these two interventions enrolled 2502 patients from 117 US and Canadian centers.
CDC Tuberculosis Clinical Trials Consortium
We have enrolled over 486 over the past 10 years to test new drugs and interventions the New Jersey site of the CDC Tuberculosis Clinical Trials Consortium, which includes 23 U.S. and International academic Institutions.
New product development for the treatment of gingival recession involves a four-site, bioequivalence study of approximately 80 subjects for the treatment of gingival recession.
Cyclophosphamide treatment of Scleroderma
Head of a national study to determine effectiveness of cyclophosphamide to improve overall lung function and reduce lung-related inflammation associated with Scleroderma. The 12-month, 13-site clinical trial involved 158 patients.
Pediatric AIDS Clinical Trials
Trial team investigating treatment consequences in HIV-infected children with prior single dose nevirapine exposure entitled: Pediatric AIDS Clinical Trials Group 1060: Parallel Randomized Clinical Trials Comparing the Responses to Initiation of NNRTI-based versus PI-based Antiretroviral Therapy in HIV-Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother to Child Transmission. This trial, rigorously designed biostatistically and targeted for three sites in South Africa, plans to enroll 480 children.
Comparative Study of Three Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers
The U.S. Department of Health and Human Services (HHS) guidelines recommend that HIV infected patients who have never received anti-HIV therapy be treated with a triple drug regimen. This Phase III comparative study of three non-nucleoside reverse transcriptase inhibitor (NNRTI)-Sparing antiretroviral regimens will look at how well different combinations of anti-HIV drugs work to decrease the amount of HIV in the blood (viral load) and allow immune system recovery in people who have never received anti-HIV therapy. This study will also examine drug tolerability and safety for the various drug combinations.
Treatment of HER-2 Positive Breast Cancer
A Phase III, randomized, open-label study of adjuvant therapy for patients with HER2-positive node-positive or high risk node-negative breast cancer, comparing the effect on disease-free survival of chemotherapy plus trastuzumab, with chemotherapy plus Herceptin plus bevacizumab. The anticipated time on study treatment is 1 year, and the target sample size is 500+ individual. Target sample size is 3500.